What Is Kisspeptin? A Complete Scientific Guide

Kisspeptin is a naturally occurring peptide that plays a central role in controlling human puberty, reproductive hormone production and fertility.

It acts near the top of the hypothalamic–pituitary–gonadal axis, the hormonal system that coordinates communication between the brain, pituitary gland and reproductive organs.

Rather than directly supplying testosterone, oestrogen or progesterone, kisspeptin stimulates specialised neurons in the hypothalamus that release:

Gonadotropin-releasing hormone, or GnRH

GnRH then signals the pituitary gland to release:

• Luteinising hormone, or LH

• Follicle-stimulating hormone, or FSH

These hormones subsequently regulate:

• Testosterone production

• Oestrogen production

• Ovulation

• Sperm production

• Menstrual cycling

• Sexual development

• Fertility

The discovery that people with defective kisspeptin signalling may fail to undergo normal puberty transformed scientific understanding of reproductive endocrinology.

Researchers are now studying kisspeptin and kisspeptin-receptor agonists in relation to:

• Infertility

• In vitro fertilisation

• Hypothalamic amenorrhoea

• Hypogonadotropic hypogonadism

• Delayed puberty

• Polycystic ovary syndrome

• Hyperprolactinaemia

• Low sexual desire

• Reproductive hormone testing

Kisspeptin is therefore one of the most biologically important reproductive peptides currently under investigation.

However, commercial claims that it universally “balances hormones,” permanently raises testosterone or safely restores libido are not supported by robust clinical evidence.

Its effects depend heavily on:

• Sex

• Baseline hormone status

• Menstrual-cycle phase

• Reproductive condition

• Dose

• Frequency of exposure

• Duration of treatment

This guide examines what kisspeptin is, how the kisspeptin system controls reproduction, what human research has shown and where major uncertainties remain.

Kisspeptin is recognised as a crucial regulator of GnRH secretion and therefore of puberty, reproductive hormone release and fertility.

What is kisspeptin?

Kisspeptin refers to a family of naturally occurring peptides produced from a larger precursor protein encoded by the KISS1 gene.

Different-length forms include:

• Kisspeptin-54

• Kisspeptin-14

• Kisspeptin-13

• Kisspeptin-10

All contain the same biologically active C-terminal region and can activate the kisspeptin receptor.

Kisspeptin-54 was originally called metastin because the KISS1 system was first investigated in relation to suppression of cancer metastasis.

Its central importance in reproductive biology was recognised later.

What is the KISS1 gene?

KISS1 is the gene that provides instructions for producing the kisspeptin precursor protein.

After production, the precursor can be processed into several shorter biologically active kisspeptins.

KISS1 expression occurs in several tissues, including:

• The hypothalamus

• Placenta

• Ovary

• Testis

• Pancreas

• Liver

• Blood vessels

Its most established physiological function is the regulation of reproductive hormone signalling through the brain.

Why is it called kisspeptin?

The name does not originate from kissing or sexual behaviour.

The KISS1 gene was discovered by researchers in Hershey, Pennsylvania, a city associated with Hershey’s chocolate “Kisses.”

The gene was initially studied for its apparent ability to reduce cancer-cell metastasis.

The peptides produced from the gene later became known collectively as kisspeptins.

What is the kisspeptin receptor?

Kisspeptin acts primarily through the kisspeptin receptor, now known as:

KISS1R

The receptor was previously called:

GPR54

KISS1R is a G-protein-coupled receptor expressed in several tissues, particularly on GnRH-producing neurons in the hypothalamus.

When kisspeptin activates KISS1R:

1. GnRH neurons become stimulated.

2. GnRH is released in pulses.

3. The pituitary gland releases LH and FSH.

4. The reproductive organs respond.

5. Sex-hormone production and reproductive function are regulated.

This signalling pathway is central to normal human fertility.

How does kisspeptin work?

Kisspeptin primarily acts upstream of GnRH.

The general pathway is:

Kisspeptin → KISS1R → GnRH → LH and FSH → reproductive organs

In males:

• LH stimulates Leydig cells in the testes to produce testosterone.

• FSH supports Sertoli-cell activity and sperm production.

In females:

• LH contributes to ovarian steroid production and ovulation.

• FSH supports follicular development and oestrogen production.

Kisspeptin therefore does not directly act like testosterone or oestrogen.

It stimulates the body’s existing reproductive signalling system.

The hypothalamic–pituitary–gonadal axis

The hypothalamic–pituitary–gonadal axis, often shortened to the HPG axis, controls reproduction.

Produces GnRH in carefully timed pulses.

Responds to GnRH by releasing LH and FSH.

The testes or ovaries respond by producing sex hormones and reproductive cells.

Sex hormones then feed information back to the hypothalamus and pituitary gland.

Kisspeptin neurons help integrate these feedback signals.

Kisspeptin and GnRH

GnRH is released from the hypothalamus in pulses.

The pulse pattern is essential.

Different GnRH pulse frequencies may produce different patterns of:

• LH release

• FSH release

• Sex-hormone production

Kisspeptin is one of the most powerful known natural stimulators of GnRH neurons.

Human studies have shown that kisspeptin administration can increase LH pulsatility, supporting its role as an upstream reproductive signal.

Kisspeptin, neurokinin B and dynorphin

Many kisspeptin neurons in the hypothalamic arcuate nucleus also produce:

• Neurokinin B

• Dynorphin

These are known collectively as KNDy neurons.

The name comes from:

• K for kisspeptin

• N for neurokinin B

• Dy for dynorphin

KNDy neurons are thought to help generate and regulate the pulsatile release of GnRH.

In simplified terms:

• Neurokinin B may help stimulate pulse activity.

• Dynorphin may help suppress or terminate each pulse.

• Kisspeptin transmits the final stimulatory signal to GnRH neurons.

This system helps explain how reproductive hormone pulses are coordinated.

Kisspeptin and puberty

One of kisspeptin’s most important roles is initiating puberty.

Before puberty, GnRH activity remains comparatively restrained.

As puberty approaches:

• Kisspeptin signalling increases.

• GnRH pulsatility strengthens.

• LH and FSH secretion rises.

• Sex-hormone production increases.

• Reproductive organs mature.

Genetic discoveries provided some of the strongest evidence for this pathway.

People with inactivating mutations affecting KISS1 or KISS1R may develop:

Congenital hypogonadotropic hypogonadism

This may result in absent or incomplete puberty and infertility.

Conversely, activating mutations in KISS1R have been associated with unusually early puberty.

These findings demonstrate that kisspeptin signalling is necessary for normal pubertal development.

Kisspeptin and fertility

Kisspeptin is essential for normal fertility because it controls the hormone cascade required for:

• Ovulation

• Menstrual cycling

• Sperm production

• Testosterone production

• Oestrogen production

• Sexual maturation

Disruption anywhere in the kisspeptin–GnRH pathway can impair reproductive function.

Researchers are therefore investigating whether kisspeptin treatment could restore reproductive hormone signalling in selected conditions.

Kisspeptin-54

Kisspeptin-54 is the longest major biologically active kisspeptin fragment.

It was originally called metastin.

Compared with kisspeptin-10, kisspeptin-54 generally has:

• A longer molecular structure

• A longer duration of biological activity

• Different pharmacokinetic properties

Kisspeptin-54 has been used in several human fertility and IVF studies.

Kisspeptin-10

Kisspeptin-10 is the shortest kisspeptin fragment that retains full receptor activity.

It contains ten amino acids and corresponds to the active C-terminal portion shared by longer kisspeptins.

Human studies have demonstrated that kisspeptin-10 can stimulate LH secretion in both men and women.

However, responses may differ according to sex and menstrual-cycle phase.

Kisspeptin-10 vs kisspeptin-54

Both kisspeptin-10 and kisspeptin-54 activate KISS1R.

However, they are not pharmacokinetically identical.

Results from one form should not automatically be applied to another without considering dose, route and duration.

Kisspeptin and LH

Luteinising hormone is often the hormone most strongly increased following kisspeptin administration.

This is because kisspeptin activates GnRH neurons, and GnRH then stimulates pituitary LH secretion.

In men, LH stimulates testosterone production.

In women, LH supports ovarian steroid production and helps trigger ovulation.

The magnitude of the LH response depends on reproductive status and hormonal context.

Kisspeptin and FSH

Kisspeptin can also influence FSH through GnRH stimulation.

However, the FSH response is often smaller or less immediate than the LH response.

FSH is important for:

• Ovarian follicle development

• Oestrogen production

• Sertoli-cell function

• Sperm production

A temporary rise in FSH does not necessarily establish improved fertility.

Kisspeptin and testosterone

Because kisspeptin can increase GnRH and LH, it may subsequently increase testosterone in some men.

However, the response depends on whether the rest of the HPG axis is functional.

For example, kisspeptin may have limited effectiveness where there is:

• Primary testicular failure

• Severe Leydig-cell dysfunction

• Pituitary disease

• Significant suppression from external hormones

• A defective downstream hormonal response

Kisspeptin is therefore not equivalent to testosterone replacement therapy.

It stimulates an upstream pathway rather than directly replacing testosterone.

Can kisspeptin restart natural testosterone production?

This claim is not established.

Kisspeptin can stimulate LH and testosterone under certain research conditions, but “restarting” a suppressed reproductive axis is considerably more complex.

Recovery may depend on:

• Cause and duration of suppression

• Testicular function

• Pituitary responsiveness

• Baseline GnRH activity

• Use of testosterone or anabolic steroids

• Other medicines

• Age

• Body composition

• General health

There are insufficient controlled trials to establish kisspeptin as a standard post-cycle or testosterone-recovery treatment.

Kisspeptin and oestrogen

In females, kisspeptin signalling is strongly influenced by oestrogen.

Oestrogen can produce both:

• Negative feedback

• Positive feedback

In much of the menstrual cycle, oestrogen helps restrain reproductive hormone release.

Before ovulation, sustained high oestrogen produces positive feedback, contributing to the LH surge.

Kisspeptin neurons are central to converting these changing oestrogen signals into appropriate GnRH activity.

Kisspeptin and ovulation

Ovulation requires a large and carefully timed LH surge.

Because kisspeptin stimulates the GnRH–LH pathway, researchers have examined whether kisspeptin can trigger final egg maturation during assisted reproduction.

Clinical studies have demonstrated that kisspeptin-54 can induce oocyte maturation in women undergoing IVF.

This has been particularly interesting for women at increased risk of ovarian hyperstimulation syndrome.

Kisspeptin and IVF

Traditional IVF commonly uses human chorionic gonadotrophin, or hCG, to trigger final egg maturation.

However, hCG can increase the risk of ovarian hyperstimulation syndrome in susceptible patients.

Kisspeptin may produce a more physiological trigger by stimulating the woman’s own GnRH and LH release.

Research has investigated kisspeptin as a potential IVF trigger because its action may be shorter and more naturally regulated than direct hCG exposure.

Kisspeptin has successfully triggered egg maturation in clinical research, but it is not yet a universal replacement for established IVF protocols.

What is ovarian hyperstimulation syndrome?

Ovarian hyperstimulation syndrome, or OHSS, is a potentially serious complication of fertility treatment.

It can involve:

• Enlarged ovaries

• Abdominal pain

• Fluid retention

• Nausea

• Breathing difficulty

• Blood-clot risk

• Kidney problems

Severe cases require specialist medical care.

Kisspeptin-based IVF triggers have been investigated partly because they may reduce the hormonal exposure that contributes to OHSS.

Kisspeptin and hypothalamic amenorrhoea

Functional hypothalamic amenorrhoea occurs when menstrual periods stop because the hypothalamus reduces GnRH signalling.

Contributing factors may include:

• Low energy availability

• Excessive exercise

• Psychological stress

• Low body weight

• Rapid weight loss

Kisspeptin administration can initially stimulate reproductive hormones in women with hypothalamic amenorrhoea.

However, repeated exposure may lead to reduced responsiveness or tachyphylaxis.

This means the effect may weaken when kisspeptin is given repeatedly.

What is tachyphylaxis?

Tachyphylaxis is a rapid reduction in response to repeated administration of a substance.

In kisspeptin research, continuous or frequent stimulation may cause:

• Receptor desensitisation

• Reduced GnRH release

• Smaller LH responses

This is important because more frequent kisspeptin exposure may not produce greater reproductive stimulation.

The timing and pattern of administration can be as important as the amount.

Kisspeptin and hypogonadotropic hypogonadism

Hypogonadotropic hypogonadism occurs when insufficient GnRH, LH or FSH signalling results in low sex-hormone production.

Symptoms may include:

• Delayed or absent puberty

• Low testosterone or oestrogen

• Infertility

• Reduced libido

• Menstrual disturbance

• Reduced sperm production

Kisspeptin may stimulate the reproductive axis where GnRH neurons and the pituitary remain capable of responding.

Studies in people with neurokinin B signalling defects have shown that kisspeptin can restore LH pulsatility, demonstrating that it can function downstream of neurokinin B.

It is unlikely to correct every form of hypogonadism.

Kisspeptin and hyperprolactinaemia

High prolactin can suppress GnRH and lead to:

• Low libido

• Menstrual disturbance

• Infertility

• Low testosterone

• Erectile dysfunction

Researchers have investigated whether kisspeptin can bypass some of this suppression by directly stimulating GnRH neurons.

Clinical research has explored intravenous and repeated subcutaneous kisspeptin administration in women with hyperprolactinaemia.

This remains investigational and does not replace treatment of the underlying cause of elevated prolactin.

Kisspeptin and polycystic ovary syndrome

Polycystic ovary syndrome, or PCOS, is associated with complex changes in:

• GnRH pulse frequency

• LH secretion

• Insulin sensitivity

• Androgen production

• Ovarian function

Some women with PCOS appear to have altered kisspeptin signalling.

Researchers are examining whether kisspeptin could act as:

• A biomarker

• A physiological probe

• A future therapeutic target

However, reported blood kisspeptin concentrations vary substantially between studies, and kisspeptin is not an established diagnostic test or standard treatment for PCOS.

Kisspeptin and menopause

Menopause occurs when ovarian follicular function declines and oestrogen production falls.

LH and FSH typically rise because reduced ovarian hormone feedback removes inhibition from the hypothalamus and pituitary.

Because the ovaries have reduced capacity to respond, kisspeptin stimulation may not restore normal premenopausal hormone production.

Kisspeptin is therefore not established as a replacement for menopausal hormone therapy.

Research into kisspeptin, neurokinin B and menopausal symptoms has helped scientists better understand reproductive neuroendocrine pathways, but therapeutic applications remain under development.

Kisspeptin and perimenopause

Perimenopause involves fluctuating ovarian function rather than complete ovarian failure.

Symptoms may include:

• Irregular cycles

• Hot flushes

• Sleep disruption

• Mood changes

• Reduced libido

• Changes in bleeding

Although kisspeptin regulates reproductive hormone signalling, there is insufficient evidence that kisspeptin treatment safely or predictably “balances hormones” during perimenopause.

Symptoms may arise from fluctuating ovarian responsiveness rather than a simple kisspeptin deficiency.

Kisspeptin and male fertility

Kisspeptin has been studied in relation to:

• LH secretion

• Testosterone production

• Sperm biology

• Hypogonadism

• Infertility

Kisspeptin and KISS1R are also expressed in the testes and reproductive tract, suggesting possible local functions beyond hypothalamic GnRH regulation.

However, serum kisspeptin measurements are not established as a routine male-fertility test.

A 2025 comparative study reported differing serum kisspeptin levels in fertile and infertile men, but such findings require larger validation before clinical use.

Kisspeptin and sperm production

FSH and intratesticular testosterone are necessary for normal sperm production.

Because kisspeptin can increase GnRH, LH and sometimes FSH, it could theoretically support spermatogenesis where upstream signalling is deficient.

However, sperm production takes several months and cannot be assessed by a short-term rise in LH or testosterone alone.

Controlled studies demonstrating improved pregnancy rates or live births in male-factor infertility remain limited.

Kisspeptin and female fertility

In women, kisspeptin contributes to:

• Follicular development

• Oocyte maturation

• Ovulation

• Menstrual-cycle regulation

• Implantation

• Pregnancy biology

The kisspeptin system is also active in the ovary, placenta and other reproductive tissues.

Evidence suggests kisspeptin may have both central and peripheral reproductive actions.

Kisspeptin and pregnancy

Kisspeptin concentrations rise dramatically during pregnancy.

The placenta produces large amounts of kisspeptin, and circulating concentrations may become thousands of times higher than outside pregnancy.

Researchers have studied kisspeptin as a potential marker of:

• Placental function

• Miscarriage risk

• Pregnancy viability

• Pre-eclampsia

• Fetal growth

Although some studies report associations, kisspeptin measurement is not yet a universally established pregnancy diagnostic test.

Kisspeptin and miscarriage

Lower kisspeptin concentrations have been associated with miscarriage risk in some observational studies.

However, an association does not prove that low kisspeptin causes miscarriage.

Levels may reflect impaired placental development rather than being the original cause.

Kisspeptin supplementation has not been established as a treatment to prevent miscarriage.

Kisspeptin and libido

Kisspeptin is frequently promoted as a libido-enhancing peptide.

The relationship is more complex than simply increasing testosterone or oestrogen.

Kisspeptin-producing neurons connect reproductive hormone signalling with brain regions involved in:

• Attraction

• Reward

• Emotion

• Sexual arousal

Human neuroimaging studies suggest kisspeptin can influence brain responses to sexual and romantic stimuli.

This has led to research into psychosexual disorders and low sexual desire.

Kisspeptin and sexual brain processing

Controlled human studies have examined kisspeptin’s effects on brain activity during exposure to sexual and emotional images.

Research has reported changes in networks associated with:

• Sexual arousal

• Attraction

• Reward

• Emotional processing

• Behavioural inhibition

A study in women with hypoactive sexual desire disorder found that kisspeptin altered sexual and attraction-related brain processing.

These findings do not mean kisspeptin is an approved treatment for low libido.

Kisspeptin and erectile responses

A placebo-controlled study in men with hypoactive sexual desire disorder reported that kisspeptin altered sexual brain processing and increased penile tumescence during sexual visual stimulation.

The study reported a larger erectile response during the experimental condition, but this remains early clinical research rather than proof of an established erectile-dysfunction treatment.

Kisspeptin should not be considered equivalent to medicines such as sildenafil.

Kisspeptin and hypoactive sexual desire disorder

Hypoactive sexual desire disorder involves persistently reduced sexual desire that causes personal distress.

It can be influenced by:

• Hormones

• Psychological health

• Relationship factors

• Medication

• Pain

• Menopause

• Chronic illness

Kisspeptin research suggests a possible role in integrating reproductive hormones with sexual motivation.

However, larger and longer clinical trials are required to establish effectiveness and safety.

Does kisspeptin increase libido?

Kisspeptin may influence sexual brain processing and reproductive hormones under controlled research conditions.

It has not been proven to consistently increase libido in the general population.

A person’s response may depend on the underlying cause of low desire.

For example, kisspeptin may not correct libido problems caused primarily by:

• Relationship distress

• Medication adverse effects

• Chronic pain

• Depression

• Severe androgen or oestrogen deficiency

• Menopausal tissue changes

Kisspeptin and anxiety

Animal studies have produced conflicting findings regarding kisspeptin and anxiety-related behaviour.

A 2025 human study reported that a biologically active dose stimulated reproductive hormones without significantly altering behavioural, biochemical or physiological measures of anxiety in the participants studied.

This provides some reassurance in the studied setting but does not establish comprehensive psychiatric safety with repeated or long-term use.

Kisspeptin and mood

Kisspeptin connects reproductive signalling with limbic brain regions involved in emotion.

Human imaging studies suggest effects on emotional and attraction-related processing.

However, kisspeptin has not been established as a treatment for:

• Depression

• Anxiety disorders

• Bipolar disorder

• Emotional blunting

Changes in brain activity do not automatically translate into meaningful mood improvement.

Kisspeptin and metabolism

Reproductive function is closely linked to energy availability.

The body may reduce fertility signalling during:

• Starvation

• Severe calorie restriction

• Very low body fat

• Excessive exercise

• Chronic illness

Kisspeptin neurons receive signals associated with metabolic status, including pathways involving:

• Leptin

• Insulin

• Energy balance

This allows the reproductive system to respond to whether the body has sufficient resources to support reproduction.

Research continues into the relationship between kisspeptin, obesity, diabetes and reproductive dysfunction.

Kisspeptin and weight loss

Kisspeptin is not an established weight-loss treatment.

Although the kisspeptin system interacts with metabolic signals, there is no robust evidence that kisspeptin reliably produces clinically meaningful fat loss.

Its main established function remains reproductive regulation.

Kisspeptin and cancer research

The KISS1 gene was originally identified because of its potential role in suppressing metastasis.

Metastasis is the spread of cancer cells from one part of the body to another.

The KISS1–KISS1R system has demonstrated complex effects in different cancers.

Depending on cancer type and biological context, signalling may be associated with:

• Reduced metastasis

• Altered tumour migration

• Changes in invasion

• Changes in cellular growth pathways

Kisspeptin should not be described as a cancer treatment.

The relationship between kisspeptin signalling and cancer is tissue specific and remains under investigation.

Kisspeptin receptor agonists

Researchers have developed longer-acting compounds that activate KISS1R.

One example is:

MVT-602, also known as TAK-448 in some development contexts.

A human study found that MVT-602 produced prolonged stimulation of reproductive hormone signalling and demonstrated potential for female reproductive disorders.

Longer-acting agonists may behave differently from naturally occurring kisspeptin fragments.

Results cannot automatically be treated as interchangeable.

Kisspeptin receptor antagonists

Kisspeptin-receptor antagonists block KISS1R activity.

They are being investigated as possible tools for conditions involving excessive reproductive hormone signalling.

Potential research areas include:

• Endometriosis

• Uterine fibroids

• Prostate cancer

• Precocious puberty

• Hormone-sensitive disease

These applications remain experimental.

Continuous vs pulsatile kisspeptin exposure

The pattern of kisspeptin exposure matters.

Short or pulsatile stimulation may activate GnRH release.

Continuous or overly frequent stimulation may cause:

• Reduced receptor responsiveness

• Desensitisation

• Reduced LH response

• Suppression after an initial rise

This is one reason kisspeptin cannot be understood simply as “more stimulation equals more hormones.”

Human clinical evidence

Kisspeptin has a stronger human evidence base than many experimental research peptides.

Human studies have demonstrated effects on:

• LH secretion

• GnRH pulsatility

• Testosterone

• Oocyte maturation

• IVF triggering

• Sexual brain processing

• Reproductive disorders

However, most studies remain:

• Small

• Short

• Conducted in specialist research settings

• Focused on physiological markers

• Not designed to establish long-term treatment safety

Kisspeptin has not yet received widespread regulatory approval as a routine medicine.

Is kisspeptin an approved medicine?

Kisspeptin is not an authorised medicine in the United Kingdom for:

• Infertility

• Low testosterone

• Low libido

• Menopause

• PCOS

• Delayed puberty

• Post-cycle hormone recovery

It remains primarily a research compound.

Clinical use within a registered study does not mean a product has general regulatory approval.

Safety

Short-term controlled studies have generally reported acceptable tolerability.

Potential adverse effects may include:

• Headache

• Flushing

• Nausea

• Dizziness

• Abdominal discomfort

• Injection-site reactions

• Temporary changes in reproductive hormones

Comprehensive long-term safety data remain limited.

Because kisspeptin stimulates reproductive hormone signalling, potential risks may vary significantly according to:

• Sex

• Age

• Pregnancy status

• Fertility condition

• Hormone-sensitive disease

• Concurrent medication

Hormone-related risks

Kisspeptin may increase GnRH, LH, FSH and downstream sex hormones.

Potential concerns include:

• Exacerbation of hormone-sensitive conditions

• Ovarian overstimulation in fertility settings

• Menstrual disruption

• Unexpected testosterone or oestrogen changes

• Reduced responsiveness with repeated administration

Specialist monitoring is required in clinical fertility research because reproductive hormone stimulation can produce significant physiological effects.

Kisspeptin and pregnancy safety

Pregnancy naturally involves very high placental kisspeptin concentrations.

This does not prove that externally administered kisspeptin is safe during pregnancy.

The timing, location and physiological regulation of naturally produced kisspeptin differ from experimental administration.

Kisspeptin should not be assumed to be safe during pregnancy or breastfeeding without specialist medical guidance.

Kisspeptin and hormone-sensitive cancer

Because kisspeptin can influence reproductive hormone release and has tissue-specific roles in cancer biology, its safety in people with hormone-sensitive cancers is uncertain.

Particular caution may be relevant in conditions involving:

• Prostate cancer

• Breast cancer

• Ovarian cancer

• Endometrial cancer

There is insufficient evidence to establish safety in these populations.

Kisspeptin and TRT

Testosterone replacement therapy suppresses hypothalamic GnRH and pituitary LH and FSH through negative feedback.

Kisspeptin may stimulate the upstream reproductive pathway, but its ability to overcome suppression during ongoing external testosterone use is uncertain.

It should not be assumed that kisspeptin will:

• Preserve fertility during TRT

• Restore testicular size

• Maintain sperm production

• Prevent HPG-axis suppression

Established fertility-preservation strategies involve specialist assessment and may include other medically supervised treatments.

Kisspeptin and anabolic steroids

Anabolic-androgenic steroids can suppress GnRH, LH and FSH.

There is insufficient evidence to establish kisspeptin as a safe or effective post-cycle therapy.

Recovery following steroid exposure depends on:

• Compounds used

• Duration

• Exposure level

• Baseline fertility

• Testicular function

• Age

• Previous cycles

Temporary hormone increases do not necessarily prove durable reproductive recovery.

Kisspeptin and HCG

Human chorionic gonadotrophin acts similarly to LH at the reproductive organs.

Kisspeptin acts further upstream by stimulating GnRH and pituitary gonadotrophins.

They are not interchangeable.

Kisspeptin and GnRH medicines

GnRH medicines include:

• GnRH agonists

• GnRH antagonists

• Pulsatile GnRH therapy

Kisspeptin acts upstream of GnRH release.

A GnRH medicine may directly stimulate or suppress pituitary signalling depending on its formulation and administration pattern.

Kisspeptin’s effects rely on functioning GnRH neurons.

Product-quality concerns

A commercial kisspeptin product may differ substantially from material used in clinical research.

Important factors include:

• Correct peptide sequence

• Whether it is kisspeptin-10 or kisspeptin-54

• Concentration accuracy

• Purity

• Sterility

• Endotoxin levels

• Degradation

• Storage conditions

• Formulation

A label that says “kisspeptin” without identifying the specific fragment provides incomplete chemical information.

Analytical testing

HPLC can help estimate peptide purity and identify some impurities.

Mass spectrometry can help confirm molecular mass and identity.

Sterility testing evaluates microbial contamination.

Endotoxin testing identifies inflammatory bacterial components that may remain even when living organisms are absent.

Advanced analytical techniques may be required to distinguish the intended peptide from structurally related fragments.

No single test proves complete product safety.

WADA status

Kisspeptin and its agonist analogues are prohibited under the World Anti-Doping Agency’s 2026 Prohibited List.

WADA introduced kisspeptins to the Prohibited List in 2024 and continues to include them under peptide hormones, growth factors, related substances and mimetics.

Athletes subject to anti-doping rules should not use kisspeptin or related agonists without an applicable therapeutic-use exemption.

Common kisspeptin myths

Fact: Kisspeptin is an upstream neuropeptide that stimulates the GnRH–LH–FSH pathway.

Fact: It may stimulate LH and downstream testosterone production where the reproductive axis can respond, but it does not supply testosterone.

Fact: Temporary hormone stimulation does not prove durable recovery from suppression.

Fact: Responses differ according to sex, hormonal state, menstrual-cycle phase and underlying disease.

Fact: Frequent or continuous exposure may lead to desensitisation and a reduced response.

Fact: Early human studies show effects on sexual brain processing, but it is not an approved libido medicine.

Fact: It may have applications in selected fertility settings, but infertility has many causes and requires specialist assessment.

Fact: Natural biological activity does not establish the safety of externally administered or repeated doses.

Fact: Kisspeptin and its agonist analogues are prohibited by WADA.

Frequently asked questions

Yes. Kisspeptin refers to a family of naturally occurring peptide hormones encoded by the KISS1 gene.

It activates KISS1R, formerly called GPR54.

Its best-established function is stimulating GnRH neurons and regulating puberty, reproductive hormones and fertility.

Yes. Human studies demonstrate that kisspeptin can stimulate LH release.

It can increase FSH, although the response is often smaller than the LH response.

It may increase testosterone in men through GnRH and LH stimulation where the downstream reproductive axis is functional.

No. It stimulates upstream hormone signalling rather than directly replacing testosterone.

This has not been established through robust clinical trials.

There is insufficient evidence to rely on it for fertility preservation during testosterone therapy.

It is not an established post-cycle therapy.

It may influence the hormones required for sperm production, but direct evidence of improved fertility outcomes remains limited.

It has successfully triggered egg maturation in IVF research and may have future roles in selected fertility disorders.

It can stimulate the GnRH–LH pathway required for egg maturation and ovulation.

It has been studied as an experimental trigger for oocyte maturation, particularly in women at increased risk of ovarian hyperstimulation syndrome.

No. It remains a research target rather than an established PCOS treatment.

It can stimulate reproductive hormone release in research settings, although repeated exposure may lead to reduced responsiveness.

Genetic and physiological evidence confirms a central role in puberty, but treatment applications require specialist clinical investigation.

It has not been established as a treatment for menopausal or perimenopausal symptoms.

“Balancing hormones” is not a precise medical effect. Kisspeptin stimulates a specific reproductive pathway and may not correct the underlying cause of a hormonal disorder.

It may influence sexual brain processing, but it has not been proven to reliably increase libido in the general population.

An early study reported increased erectile responses during sexual visual stimulation in men with low sexual desire, but it is not an approved erectile-dysfunction treatment.

Human brain-imaging studies suggest it may influence processing of sexual and romantic stimuli.

A 2025 human study did not find significant anxiety effects from a biologically active dose, but long-term psychiatric safety remains insufficiently characterised.

It may influence brain networks involved in emotion, but it is not an established treatment for mood disorders.

No robust evidence establishes it as a weight-loss treatment.

Yes. Placental kisspeptin concentrations rise dramatically during pregnancy and may relate to placental function.

No. It has not been established as a miscarriage-prevention treatment.

External kisspeptin administration cannot be assumed to be safe during pregnancy or breastfeeding.

Kisspeptin-10 is the shortest fragment that retains full KISS1R activity.

Kisspeptin-54 is a longer naturally occurring kisspeptin form formerly known as metastin.

Neither can be described as universally better. Their duration and research applications differ.

Hormonal changes can occur relatively quickly in controlled studies, but onset varies with the form, dose and participant.

Duration differs between kisspeptin-10, kisspeptin-54 and longer-acting agonists.

Yes. Repeated or continuous stimulation may cause tachyphylaxis or receptor desensitisation.

No. It is not an authorised routine UK medicine.

Yes. Kisspeptin and its agonist analogues are prohibited.

No. Animal studies help explain mechanisms, but controlled human trials are required to establish clinical effectiveness and safety.

Kisspeptin research in context

Current evidence strongly supports kisspeptin’s role in:

• Puberty

• GnRH stimulation

• LH secretion

• Reproductive hormone regulation

• Fertility

• Ovulatory signalling

Human genetic mutations, physiological studies and clinical experiments all support this central reproductive role.

Early human research suggests possible future applications in:

• IVF triggering

• Hypothalamic amenorrhoea

• Hypogonadotropic hypogonadism

• Hyperprolactinaemia

• Psychosexual disorders

• Selected reproductive hormone conditions

Researchers have not yet established:

• Long-term treatment safety

• Optimal dosing schedules

• Long-term fertility outcomes

• Reliable treatment of low libido

• Effectiveness for post-TRT recovery

• Effectiveness as post-cycle therapy

• Safety in hormone-sensitive cancers

• Routine effectiveness in PCOS

• Safety during pregnancy

• Comparative effectiveness against established fertility treatments

Key takeaways

Kisspeptin is a naturally occurring neuropeptide encoded by the KISS1 gene.

It activates KISS1R on GnRH neurons and stimulates the reproductive hormone cascade:

Kisspeptin → GnRH → LH and FSH → sex hormones and fertility

It is essential for:

• Normal puberty

• Testosterone production

• Oestrogen signalling

• Ovulation

• Sperm production

• Fertility

Human research has demonstrated that kisspeptin can:

• Increase LH

• Influence testosterone

• Restore reproductive hormone pulsatility in selected conditions

• Trigger oocyte maturation during IVF research

• Alter sexual and emotional brain processing

However, kisspeptin is not an approved UK treatment for low testosterone, infertility, low libido, menopause or post-cycle recovery.

Repeated exposure may reduce responsiveness.

Long-term safety and clinical effectiveness remain insufficiently established.

Kisspeptin and its agonist analogues are prohibited by WADA.

Glossary

FSH: Follicle-stimulating hormone, involved in ovarian follicle development and sperm production.

GnRH: Gonadotropin-releasing hormone, the hypothalamic hormone that stimulates LH and FSH secretion.

GPR54: The former name for the kisspeptin receptor, now called KISS1R.

HPG axis: The hypothalamic–pituitary–gonadal axis controlling reproductive hormones.

Hypogonadism: Reduced reproductive-organ function resulting in low sex hormones or impaired fertility.

KISS1: The gene that encodes the kisspeptin precursor.

KISS1R: The receptor activated by kisspeptin.

KNDy neurons: Hypothalamic neurons that produce kisspeptin, neurokinin B and dynorphin.

LH: Luteinising hormone, involved in testosterone production and ovulation.

Metastin: The original name for kisspeptin-54.

Neuropeptide: A peptide involved in nervous-system signalling.

Oocyte: An immature egg cell.

OHSS: Ovarian hyperstimulation syndrome.

Tachyphylaxis: A rapid reduction in response after repeated exposure.

This article is provided for educational purposes only.

It is not intended to diagnose, treat or prevent disease or to replace advice from a qualified healthcare professional.

Kisspeptin is not an authorised medicine in the United Kingdom for infertility, low testosterone, low libido, menopause or hormonal recovery.

Although human research confirms that kisspeptin is a powerful regulator of GnRH, LH, FSH and fertility, its long-term safety and effectiveness as a treatment remain incompletely established.

Kisspeptin and its agonist analogues are prohibited by the World Anti-Doping Agency.